DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Anavex Life Sciences Corp. (AVXL) and Lead Plaintiff Deadline: February 29, 2016

NEW YORK, NY / ACCESSWIRE / February 10, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the U.S. District Court for the Southern District of New York under 15-cv-10162, is on behalf of those who purchased shares of Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) between May 17, 2013 and December 28, 2015, inclusive (the “Class Period”). Such investors are advised to contact Peretz Bronstein or his investor relations analyst Yael Hurwitz at info@bgandg.com or 212-697-6484.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Anavex had used a paid stock promoter to artificially inflate the Company’s share price; and (ii) as a result of the foregoing, Anavex’s public statements were materially false and misleading at all relevant times.

Anavex, the clinical-stage biopharmaceutical company that designs therapeutic treatments of neurodegenerative diseases, reported their year-end results for fiscal year 2015. On December 29, 2015, pre-market, the company disclosed that on December 22, 2015 the U.S. Securities and Exchange Commission had subpoenaed the company. Anavex stated, in part, that “[t]he Company believes the subpoena and investigation relate to the recent unusual activity in the market for the Company’s shares.” Following this news, on December 29, 2015, Anavex stock stock fell $0.72, or 10.24%, to close at $6.31 on December 29, 2015, trading on heavy volume.

On December 30, 2015, pre-market, Seeking Alpha’s Melissa Davis published an article called “Anavex: A Regulatory Target Damaged By Incriminating Evidence” (the “Davis Report”). Following this news, Anavex stock fell $0.78, or 12.42%, to close at $5.50 on December 30, 2015.

No Class has yet been certified in the above action. If you wish to review a copy of the Complaint and to join this action, please visit the firm’s site:http://www.bgandg.com/#!avxl/a2yk0. To discuss this action, or have any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Anavex, you have until February 29, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 436612